All
Expert Insights: Ramiro Ribeiro, MD, PhD, discusses next steps in EYP-1901 research
Ramiro Ribeiro, MD, PhD, shares insights from the ongoing research tyrosine kinase inhibitors for AMD and DME.
Italian study illuminates positive outcomes and common complications of SING IMT implantation
The implant was tested in eyes of patients with bilateral age-related macular degeneration who underwent cataract surgery
Refractory nAMD responds well to faricimab
4DMT to host webcast on interim 52-week data from Phase 2b of its PRISM clinical trial
The data will be presented virtually at Angiogenesis, Exudation, and Degeneration 2025 on February 8 and February 10, 2025.
Expert insights: Ashkan Abbey, MD discusses 1-year results of DAVIO-2 trial
Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.
Study investigates neurological impact of diabetic vitreous hemorrhage
Researchers reported identifying changes in 4 areas of the brain
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.
Notal Vision publishes positive results from pivotal study of AI algorithm in home-based OCT system
Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.
COVID-19 and the effects on the retinal microvascular structure
Optical coherence tomography angiography (OCTA) was performed in all participants; the choroidal and retinal changes were examined and recorded.
Prevent Blindness again names February as AMD and Low Vision Awareness Month
The company offers year-round educational services on the conditions, using this month in particular to guide patients to needed resources.
Beacon Therapeutics receives Regenerative Medicine Advanced Therapy designation for laruparetigene zovaparvovec (laru-zova)
Laru-zova is a gene therapy currently being investigated for the treatment of patients with X-linked retinitis pigmentosa.
Ophthalmic complications observed in patients taking semaglutide and tirzepatide
The main outcomes were the measurements of the visual acuity and visual field defects.
Successful treatment of RPE65-mediated inherited retinal dystrophy with voretigene neparvovec
Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated inherited retinal dystrophy achieved encouraging efficacious results.
SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel
The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections
MACUSTAR receives additional EMA support for AMD clinical study
The scientific outputs from MACUSTAR’s study could impact more than 200 million patients with AMD globally
AI Optics’ portable Sentinel Camera gains FDA 510(k) clearance
The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.
Harrow launches Harrow Cares program in partnership with Cencora
The program will deliver a range of high-quality access and affordability services for retina specialists.
A study of the 3-year clinical outcomes in geographic atrophy
Among these eyes, 18.9% of eyes developed nAMD within 36 months.
Apellis Pharmaceuticals receives approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy in Australia
The approval of Syfovre makes it the first and only approved treatment for GA in Australia.
Viralgen and Axovia Therapeutics partner to manufacture gene therapy for Bardet-Biedl Syndrome
The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the genetic defects in the BBS1 gene.
Tyrosine kinase inhibitor: An alternative treatment for non–small-cell lung cancer metastasis to the choroid
Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment outcomes after targeted therapy compared with conventional radiotherapy and/or chemotherapy.
Researchers identify 'triangle sign' as key diagnostic marker in ocular pathologies
The “Triangle sign” seen on ultrasound is a “distinctive and reliable” ultrasound feature for differentiating total choroidal detachments and suprachoroidal hemorrhages.
10-year data shows progressive visual decline in myopic children and adults
Effects of premature birth on the retina of adults
The investigators found that the premature births to be associated with vascular changes on ocular coherence tomography-angiography.
NeurEYE team leads AI research to detect dementia through retinal imaging
The NeurEYE research team will use millions of eye scans from Scottish optometrists to create the data set.
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, receives approval for suprachoroidal treatment for uveitic macular edema in Australia and Singapore
ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.
FDA grants fast track designation to N-acetylcysteine amide tablets from Nacuity Pharmaceuticals
The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa.
HELIOS trial: Promising 1-Year results of phase I study for treating NPDR
DRSS stable/improved with OKT-TKI; drug well tolerated
Potential effect of temperature changes on anti-VEGF drugs
Home-stored anti-VEGF drugs face risks from temperature changes, pointing to a need to protect efficacy and avoid dangerous contamination.
PulseSight Therapeutics submits Clinical Trial Authorization for phase I trial of PST-611
The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy